Skip to main content

Medpace Holdings, Inc.

corporate_fare Company Profile

Medpace Holdings, Inc.

MEDP·NASDAQ·Industrial Applications And Services·CIK 0001668397

Medpace Holdings, Inc. is a global clinical contract research organization (CRO) that provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company's mission is to accelerate the global development of safe and effective medical therapeutics. Medpace focuses on delivering full-service Phase I-IV clinical development services, emphasizing a disciplined operating model and therapeutic expertise to provide timely and cost-effective results. Medpace aims to be a partner of choice for small and mid-sized biopharmaceutical companies, consistently utilizing its full-service, disciplined operating model to deliver high-quality results. The company's business strategy involves expanding its market share in the growing Phase I-IV CRO market by conducting clinical trials across all major therapeutic areas. Medpace demonstrates particular strength in Oncology, Metabolic, Cardiology, Antiviral and Anti-infective (AVAI), and Central Nervous System (CNS). The company generates revenue by offering a full suite of services that support the entire clinical development process, from Phase I to Phase IV, across various therapeutic areas. Before a new drug can be commercialized, it typically undergoes extensive pre-clinical and clinical testing and regulatory review to verify safety and efficacy. Medpace's services include a medical department with therapeutic leads who provide strategic direction for study design and planning, train operational staff, work with primary investigators, offer medical monitoring, and meet with regulatory agencies. Clinical trial management is led by clinical trial managers (CTMs) who oversee all aspects of study execution and drive accountability. CTMs utilize ClinTrak, Medpace's proprietary information management system for clinical trials, which is integrated with standard operating procedures (SOPs) to provide real-time study metrics.

Medpace Holdings, Inc. (NASDAQ:MEDP) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 21 items for MEDP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-22, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 9 rated 8 or above. Recent SEC coverage for MEDP spans 10-Q, 8-K, SCHEDULE 13D/A, 144.

Recent high-impact activity:

  • Medpace 10-Q: Q3 EPS $4.84, All Book-to-Bill Suits Dismissed, New $1.0B Buyback
  • Medpace Beats on Q3 EPS, Authorizes New $1.0B Buyback Through 2028
  • Medpace Posts 3Q EPS of $4.84
  • Medpace Chairman Troendle Sold ~$125M in Stock Over Six Weeks
  • Chairman Troendle Files to Sell $184.8M in Medpace Stock

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.53B
Net Income
$451.12M
Diluted EPS
$15.28
Op. Cash Flow
$713.22M
Free Cash Flow
$681.87M
Operating Income
$534.93M
Cash & Equivalents
$497.05M
Debt / Equity
0.00×
Net Margin
17.8%
Shares Outstanding
28.37M sh
Source: 10-K · filed 2026-02-10 · accession 0001668397-26-000006

Short Interest & Short Volume

3.46 days to cover

FINRA reported short interest of 1,384,347 shares in MEDP as of the October 30, 2026 settlement, a 14.1% decrease from the prior period — about 3.5 days to cover at its recent average daily volume. On November 20, 2026, 45.3% of MEDP volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,384,347 shares as of October 30, 2026
Change vs prior period▼ 14.1%
Days to cover3.46 at avg daily volume of 399,615
Daily short volume (FINRA facilities)45.3% of 113,378 shares on November 20, 2026
5-day average short volume48.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with M →
$605.49 -0.83% today
52-week range · as of 2026-10-22 $373 – $684.52
Market cap
$17.08B
Volume
236.8K (0.8× avg)
3-mo avg 283.9K
Live data · 2026-11-22 12:42 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MEDP - Latest Insights

MEDP
Oct 22, 2026, 4:02 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $653.96
Real-time Price: $605.49 info
Change: -$48.47 (-7%) info
Market Cap: $17.078B info
MEDP
Oct 21, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $635.00
Real-time Price: $605.49 info
Change: -$29.51 (-5%) info
Market Cap: $17.078B info
MEDP
Oct 21, 2026, 4:15 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $661.00
Real-time Price: $605.49 info
Change: -$55.51 (-8%) info
Market Cap: $17.078B info
MEDP
Sep 28, 2026, 7:15 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $615.94
Real-time Price: $605.49 info
Change: -$10.45 (-2%) info
Market Cap: $17.078B info
MEDP
Jul 27, 2026, 4:52 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $589.37
Real-time Price: $605.49 info
Change: +$16.12 (+3%) info
Market Cap: $17.078B info
MEDP
Jul 23, 2026, 4:03 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $602.02
Real-time Price: $605.49 info
Change: +$3.47 (+0.58%) info
Market Cap: $17.078B info
MEDP
Jul 22, 2026, 4:34 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $605.00
Real-time Price: $605.49 info
Change: +$0.490 (+0.08%) info
Market Cap: $17.078B info
MEDP
Jun 16, 2026, 4:23 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $461.60
Real-time Price: $605.49 info
Change: +$143.89 (+31%) info
Market Cap: $17.078B info
MEDP
Jun 04, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $458.69
Real-time Price: $605.49 info
Change: +$146.80 (+32%) info
Market Cap: $17.078B info
MEDP
May 26, 2026, 6:18 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $432.80
Real-time Price: $605.49 info
Change: +$172.69 (+40%) info
Market Cap: $17.078B info
MEDP
May 19, 2026, 2:43 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $423.59
Real-time Price: $605.49 info
Change: +$181.90 (+43%) info
Market Cap: $17.078B info
MEDP
May 12, 2026, 6:46 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $417.29
Real-time Price: $605.49 info
Change: +$188.20 (+45%) info
Market Cap: $17.078B info
MEDP
Apr 22, 2026, 4:26 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $430.00
Real-time Price: $605.49 info
Change: +$175.49 (+41%) info
Market Cap: $17.078B info
MEDP
Apr 22, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $420.01
Real-time Price: $605.49 info
Change: +$185.48 (+44%) info
Market Cap: $17.078B info
MEDP
Apr 22, 2026, 4:15 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $420.00
Real-time Price: $605.49 info
Change: +$185.49 (+44%) info
Market Cap: $17.078B info
MEDP
Apr 01, 2026, 4:42 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $489.48
Real-time Price: $605.49 info
Change: +$116.01 (+24%) info
Market Cap: $17.078B info
MEDP
Mar 19, 2026, 4:45 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $460.92
Real-time Price: $605.49 info
Change: +$144.57 (+31%) info
Market Cap: $17.078B info
MEDP
Mar 17, 2026, 12:37 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $452.27
Real-time Price: $605.49 info
Change: +$153.22 (+34%) info
Market Cap: $17.078B info
MEDP
Mar 16, 2026, 5:23 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $453.64
Real-time Price: $605.49 info
Change: +$151.85 (+33%) info
Market Cap: $17.078B info
MEDP
Feb 10, 2026, 4:03 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $446.05
Real-time Price: $605.49 info
Change: +$159.44 (+36%) info
Market Cap: $17.078B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets